公司資料
Rallybio 股價、新聞與催化劑
- 股票代碼:
- RLYB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
16.93 USD (-1.51%)
收盤價
最後更新: 2026年9月21日
94.1M USD
市值
股價為何變動
截至 2026年9月21日，RLYB 下跌 1.51%，收於 $16.93。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Rallybio sits in specialty biotechnology.
商業模式特徵
The business depends on clinical proof, pipeline selection, and the ability to create value in rare-disease markets.
生技產業定位
Rallybio is a rare-disease catalyst name whose valuation is closely linked to proof-of-concept and strategy.
未來催化劑
- Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path. The stock tends to respond quickly if the next update shows the platform still has room to run.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。